[EN] TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS<br/>[FR] COMPOSÉS TRICYCLIQUES EN TANT QU'INHIBITEURS DE MPGES-1
申请人:GLENMARK PHARMACEUTICALS SA
公开号:WO2012110860A1
公开(公告)日:2012-08-23
The present invention relates to tricyclic compounds of formula (I) or pharmaceutically acceptable salt thereof as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase- 1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthama, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases. (I).
本发明涉及式(I)的三环化合物或其药用可接受的盐,作为mPGES-1抑制剂。这些化合物是微粒体前列腺素E合成酶-1(mPGES-1)酶的抑制剂,因此在治疗各种疾病或症状引起的疼痛和/或炎症方面具有用处,如哮喘、骨关节炎、类风湿性关节炎、急性或慢性疼痛和神经退行性疾病。